Pharmacological and neurosurgical management of cerebral palsy and dystonia: Clinical practice guideline update

Dystonia, typically characterized by slow repetitive involuntary movements, stiff abnormal postures, and hypertonia, is common among individuals with cerebral palsy (CP). Dystonia can interfere with activities and have considerable impact on motor function, pain/comfort, and ease of caregiving. Although pharmacological and neurosurgical approaches are used clinically in individuals with CP and dystonia that is causing interference, evidence to support these options is limited. This clinical practice guideline update comprises 10 evidence-based recommendations on the use of pharmacological and neurosurgical interventions for individuals with CP and dystonia causing interference, developed by an international expert panel following the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. The recommendations are intended to help inform clinicians in their use of these management options for individuals with CP and dystonia, and to guide a shared decision-making process in selecting a management approach that is aligned with the individual's and the family's values and preferences. This clinical practice guideline provides evidence-based clinical recommendations for the use of pharmacological and neurosurgical management options for individuals with dystonia and cerebral palsy (CP), alongside practical considerations and suggestions for future research priorities. It was developed by a panel of clinicians with diverse expertise following the GRADE process, with constructive input from individuals with CP and dystonia and their families.image